6 terminated, 4 completed, 3 recruiting, 1 active not recruiting. 15 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Terminated 6, Completed 4, Recruiting 3, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 6 | Terminated 3, Completed 1, Recruiting 1, Withdrawn 1 |
Follow ECG: new trials by email Literature Review of ECG trials Research Report on ECG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride - Malignant Digestive System Neoplasm | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 60 | 2026-04-30 | 2026-06-02 |
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2023-11-14 | 2025-12-02 |
| BMS-986253 in Myelodysplastic Syndromes Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253 - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2022-11-29 | 2025-09-30 |
| Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma LMB-100, ipilimumab, Diphenhydramine - Mesothelioma | Phase 1 | Terminated | National Cancer Institute (NCI) | 2 | 2021-06-11 | 2024-02-02 |
| Study of Codivir in Patients With COVID-19 Covidir injections, One Step Test, IgM and IgG dosage - Covid19 | Phase 1 | Completed | Code Pharma | 12 | 2021-03-29 | 2021-11-02 |
| Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 32 | 2021-01-14 | 2026-07-14 |
| The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females Zolpidem, ECG - Prostatic Neoplasms | Phase 1 | Terminated | National Cancer Institute (NCI) | 12 | 2019-01-22 | 2026-06-26 |
| Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) Durvalumab, Vicineum, Acetaminophen - Urinary Bladder Neoplasms | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2018-06-07 | 2026-10-27 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 54 | 2018-03-26 | 2025-06-04 |
| Next Generation Personalized Neuroblastoma Therapy Biopsy, Next Generation Sequencing, Tumor Scans - Neuroblastoma, Cancer | Phase 1 | Terminated | Yael P Mosse | 66 | 2016-07-01 | 2026-03-10 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer EP0057, olaparib, CT scan - Urothelial Carcinoma, Urothelial Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 45 | 2016-05-09 | 2026-08-13 |
| Positron Emission Tomography (PET) Imaging of Thrombosis [64Cu]FBP8, PET/MR, Blood Collection - Atrial Fibrillation, COVID-19 | Phase 1 | Recruiting | Massachusetts General Hospital | 165 | 2016-04-01 | 2026-02-27 |
| Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Rituximab, Conditioning chemotherapy, TMS - Myelodysplastic Syndromes, Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 34 | 2015-09-24 | 2025-09-30 |
| Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2014-05-20 | 2026-11-12 |
Myelodysplastic Syndromes (4) · COVID-19 (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Neoplasms (2) · Prostatic Neoplasms (2) · Atrial Fibrillation (1) · Bone Marrow Diseases (1) · Burkitt Lymphoma (1) · Carcinoma in Situ (1) · Carcinoma, Transitional Cell (1) · Coronavirus Infections (1) · Cytopenia (1) · Gastrointestinal Neoplasms (1)
National Cancer Institute (NCI) (9) · Code Pharma (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1) · Thomas Jefferson University (1) · Yael P Mosse (1)
United States (13) · Brazil (1)
Najla El Jurdi, M.D. (2) · Alain Mina, M.D. (1) · Anish Thomas, M.D. (1) · Chetan Jeurkar, DO (1) · Ciprian Catana, PhD (1) · Elie Traer, MD PhD (1) · Eynat Finkelshtein (1) · Joerg Herrmann, MD (1) · John M Maris, MD (1) · Kieron Dunleavy (1) · Nirali N Shah, M.D. (1) · Raffit Hassan, M.D. (1) · Raju Chelluri, M.D. (1) · William D Figg, Pharm.D. (1)
PMID 32897402, PMID 34656469, PMID 34687939, PMID 34889384, PMID 35605184, PMID 37486616, PMID 38376944, PMID 40331908, PMID 41180818, PMID 41425223, PMID 42248607, PMID 42820295
2015 (1), P30CA051008 (1), R01HL109448 (1)